Bioretec Completes 7.2 M€ Equity Funding Round

Bioretec´s investment round was oversubscribed and ended during the first subscription day.

”We are extremely delighted about the investors’ interest and trust towards our company and our innovative products. I would like to express my warmest gratitude to all the subscribers as well as to the professional team of Springvest for their work in coordinating and marketing of our investment round. We strongly believe that our products can provide considerable benefits to patients across the world – and accordingly this will lead into increased shareholder value”, summarizes Tomi Numminen, Bioretec´s Chairman of the Board of Directors.

The company focuses to the registration and commercialization of RemeOs™ trauma screws

”Our new production facilities are almost ready and RemeOs™ Screw registration process has been started with the U.S. FDA. The United States Food and Drug Administration FDA granted Breakthrough Device Designation for Bioretec’s bioresorbable RemeOs™ Screw and the on-going interactive process with the FDA forms a foundation to our registration process. We have a talented and motivated team and our groundbreaking pipeline consits of various next-generation bioresorbable products. We are accelerating forward to reach our operative targets”, comments Timo Lehtonen, CEO of the company.

Bioretec investment round was organized by Springvest Oy

”We have known Bioretec team extremely well already for years and wanted to organize this exciting investment round. We knew that Bioretec shares shall show strong demand  in the markets”, states Päivi Malinen, Springvest’s CEO.

SourceBioretec
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy